A Novel Treatment for Malarial Infections

The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary in vivo testing of these compounds in a mouse malaria model is currently ongoing.

Potential Commercial Applications: Competitive Advantages:
Treatment of malarial infections  
  • Novel drug treatment for malarial infections
  • Synergistic effect of these compounds on PSAC

Sanjay Desai (NIAID)

Intellectual Property:
PCT Application No. PCT/US09/50637
US Application No. 61/083,000
US Application No. 13/055,104

Kang M, et al. PMID 15843600
Desai SA, et al. PMID 10984055

Licensing Contact:
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220

OTT Reference No: E-202-2008/0

Updated: 02/13/2012